Cargando…

Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis

BACKGROUND: Intensive care unit (ICU) patients with the most severe forms of acute coronary syndrome (ACS) require invasive therapies such as extracorporeal life support. The risk of bleeding in ICU patients with ACS treated with a dual antiplatelet therapy of aspirin and ticagrelor is unknown. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Charpentier, Thibault, Ferdynus, Cyril, Lair, Thomas, Cordier, Charlotte, Brulliard, Caroline, Valance, Dorothée, Emery, Malo, Caron, Margot, Allou, Nicolas, Allyn, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197796/
https://www.ncbi.nlm.nih.gov/pubmed/32365100
http://dx.doi.org/10.1371/journal.pone.0232768
_version_ 1783528884361232384
author Charpentier, Thibault
Ferdynus, Cyril
Lair, Thomas
Cordier, Charlotte
Brulliard, Caroline
Valance, Dorothée
Emery, Malo
Caron, Margot
Allou, Nicolas
Allyn, Jérôme
author_facet Charpentier, Thibault
Ferdynus, Cyril
Lair, Thomas
Cordier, Charlotte
Brulliard, Caroline
Valance, Dorothée
Emery, Malo
Caron, Margot
Allou, Nicolas
Allyn, Jérôme
author_sort Charpentier, Thibault
collection PubMed
description BACKGROUND: Intensive care unit (ICU) patients with the most severe forms of acute coronary syndrome (ACS) require invasive therapies such as extracorporeal life support. The risk of bleeding in ICU patients with ACS treated with a dual antiplatelet therapy of aspirin and ticagrelor is unknown. The primary objective of this study was to compare the bleeding risk of ticagrelor and clopidogrel in ICU patients with ACS. METHODS AND FINDINGS: We conducted a retrospective study based on a propensity score and a proportional hazards model. All patients with ACS hospitalized in the ICU of a French university hospital between January 2013 and January 2017 were included in the study. Bleeding during ICU stay was defined as all Thrombolysis in myocardial infarction (TIMI) major or minor events. A total of 155 patients were included in the study. According to propensity score matching, 57 patients treated with aspirin and ticagrelor were matched with 57 patients treated with aspirin and clopidogrel. Median (first-third quartile) Simplified Acute Physiology Score II was 61.5 (41.0–85.0). Bleeding during ICU stay occurred in 12 patients (21.1%) treated with clopidogrel and in 35 patients (61.4%) treated with ticagrelor (p<0.0001). This significant association was found for both TIMI major bleeding (12.3% vs. 35.1%, p = 0.004) and TIMI minor bleeding (8.8% vs. 26.3%, p = 0.01). The relative risk of bleeding occurrence during ICU stay was 2.60 (confidence interval 95%: 1.55–4.35) for ticagrelor compared to clopidogrel. No significant difference in ICU mortality was found between the two groups (45.6% in the clopidogrel group vs. 29.8% in the ticagrelor group, p = 0.08). CONCLUSIONS: Bleeding complications are frequent and serious in ICU patients with ACS. A dual antiplatelet therapy of aspirin and ticagrelor is associated with a higher risk of bleeding compared to a dual antiplatelet therapy of aspirin and clopidogrel.
format Online
Article
Text
id pubmed-7197796
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-71977962020-05-12 Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis Charpentier, Thibault Ferdynus, Cyril Lair, Thomas Cordier, Charlotte Brulliard, Caroline Valance, Dorothée Emery, Malo Caron, Margot Allou, Nicolas Allyn, Jérôme PLoS One Research Article BACKGROUND: Intensive care unit (ICU) patients with the most severe forms of acute coronary syndrome (ACS) require invasive therapies such as extracorporeal life support. The risk of bleeding in ICU patients with ACS treated with a dual antiplatelet therapy of aspirin and ticagrelor is unknown. The primary objective of this study was to compare the bleeding risk of ticagrelor and clopidogrel in ICU patients with ACS. METHODS AND FINDINGS: We conducted a retrospective study based on a propensity score and a proportional hazards model. All patients with ACS hospitalized in the ICU of a French university hospital between January 2013 and January 2017 were included in the study. Bleeding during ICU stay was defined as all Thrombolysis in myocardial infarction (TIMI) major or minor events. A total of 155 patients were included in the study. According to propensity score matching, 57 patients treated with aspirin and ticagrelor were matched with 57 patients treated with aspirin and clopidogrel. Median (first-third quartile) Simplified Acute Physiology Score II was 61.5 (41.0–85.0). Bleeding during ICU stay occurred in 12 patients (21.1%) treated with clopidogrel and in 35 patients (61.4%) treated with ticagrelor (p<0.0001). This significant association was found for both TIMI major bleeding (12.3% vs. 35.1%, p = 0.004) and TIMI minor bleeding (8.8% vs. 26.3%, p = 0.01). The relative risk of bleeding occurrence during ICU stay was 2.60 (confidence interval 95%: 1.55–4.35) for ticagrelor compared to clopidogrel. No significant difference in ICU mortality was found between the two groups (45.6% in the clopidogrel group vs. 29.8% in the ticagrelor group, p = 0.08). CONCLUSIONS: Bleeding complications are frequent and serious in ICU patients with ACS. A dual antiplatelet therapy of aspirin and ticagrelor is associated with a higher risk of bleeding compared to a dual antiplatelet therapy of aspirin and clopidogrel. Public Library of Science 2020-05-04 /pmc/articles/PMC7197796/ /pubmed/32365100 http://dx.doi.org/10.1371/journal.pone.0232768 Text en © 2020 Charpentier et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Charpentier, Thibault
Ferdynus, Cyril
Lair, Thomas
Cordier, Charlotte
Brulliard, Caroline
Valance, Dorothée
Emery, Malo
Caron, Margot
Allou, Nicolas
Allyn, Jérôme
Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis
title Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis
title_full Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis
title_fullStr Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis
title_full_unstemmed Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis
title_short Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis
title_sort bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: a propensity-score matching analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197796/
https://www.ncbi.nlm.nih.gov/pubmed/32365100
http://dx.doi.org/10.1371/journal.pone.0232768
work_keys_str_mv AT charpentierthibault bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT ferdynuscyril bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT lairthomas bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT cordiercharlotte bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT brulliardcaroline bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT valancedorothee bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT emerymalo bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT caronmargot bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT allounicolas bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis
AT allynjerome bleedingriskofticagrelorcomparedtoclopidogrelinintensivecareunitpatientswithacutecoronarysyndromeapropensityscorematchinganalysis